Quality Comes First

COUNTRIES

CONTACT US

Our Pipeline and Products

Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.

Read more

MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.

Share your partnering idea

Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.

 

Contact Us

Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.

Our Values

Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.

 

Read more

What does it really make Menarini unique? The diversity and authenticity of our key resource - the People.
Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.

Available positions on Linkedin

Menarini employees make all the difference, every day.

 

Follow Us On Linkedin

News

2017-09-12

Oncology Research: new opportunities for Menarini and OBT


Oncology Alliance between Menarini & Oxford BioTherapeutics Progresses Second Candidate MEN1309 into the Clinic, an Antibody Drug Conjugate for the treatment of solid tumors and NHL

POMEZIA, Italy and OXFORD, England, September 12, 2017. Menarini Ricerche (Menarini Group) and Oxford BioTherapeutics (OBT), an international biotechnology company, announce today that they have initiated a multicenter first-in-human clinical study to evaluate MEN1309, an antibody drug conjugate for the treatment of metastatic solid cancers, as well as for the treatment of non-Hodgkin’s lymphoma.

The phase I study of MEN1309 will be conducted in major European oncology centers in Italy, Spain, Belgium and the UK. MEN1309 is a fully-human monoclonal IgG1 antibody coupled to DM4, a maytansinoid toxin targeting the tumour antigen CD205.  In patient derived models and xenografts, MEN1309 showed strong anti-tumor activity in triple-negative breast (TNBC), pancreatic, and bladder cancers, as well as diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma (NHL), consistent with the expression of CD205 seen in these cancer types.

“MEN1309 could become an innovative treatment option for many cancer patients” said Andrea Pellacani (General Manager, Menarini Ricerche). “We are very pleased with the progress of our strategic oncology alliance with Oxford BioTherapeutics. Menarini has a long-standing commitment to advancing the treatment of cancer, and we look forward to accelerating our shared pipeline with OBT in clinical development.”

This open label trial will start by enrolling patients with solid tumors in the first dose escalation phase, followed by a second dose escalation in NHL. The subsequent expansion cohorts phase will aim at identifying the recommended phase II dose in specific indications among solid tumors and NHL. In addition, the trial will investigate the correlation of the clinical response with  target antigen expression.

“We are delighted to initiate clinical development of the second oncology programme in our partnership with the Menarini Group” said Christian Rohlff, Oxford BioTherapeutics’ CEO. “By bringing together OBT’s world-class discovery capabilities with Menarini’s clinical development and manufacturing expertise, the partnership is successfully advancing exciting programs aimed at large unmet clinical need in oncology.”

Under the collaboration, Menarini is responsible for the clinical development, up to the clinical proof of concept study, and then for the full development and regulatory approval in its territories: Europe, Asia, and Latin America. OBT is responsible for full development, approval and commercialization in North America and Japan.

MEN1112, the first program from the collaboration for the treatment of Acute Myeloid Leukemia (AML), is currently progressing through the phase I dose escalation trial in relapsed/refractory AML patients.

Fraud Warning Disclaimer

Please be aware that certain individuals might approach you by falsely presenting themselves as our employees, affiliates, agents or representatives. Under this false pretense, they might try to gain access to your personal information or to acquire money or other valuables from you by offering fictitious employment opportunities or by claiming that they are contacting you on our behalf. The contacting individual or organisation may, for example, claim that we can guarantee your employment if you pay them a certain amount of money. Such fraudulent offers and claims are usually received via email, the internet, text message, phone, etc. These claims and offers are fraudulent and invalid and you are strongly advised to exercise great caution when you receive such an offer of employment or notice. Be very mindful of such scams.Below we list some of the features such an offer or claim may have:

Below we list some of the features such an offer or claim may have:

• It may propose a phone or instant message program interview and/or money as a precondition for hiring You may be requested to disclose private, sensitive or confidential information

• You may be told that you were contacted in such a manner because it is a matter of urgency

Such an offer or claim will probably be in the form of an email sent from a fake email address or from a free email address and not from an official Menarini Group email address. Please take extra caution while examining such an email address, as the perpetrators may misspell an official Menarini Group email address and use a slightly modified version of an official Menarini Group email address.

Please note that you will never receive a fraudulent employment offer or any other similar claim from us, because we do not provide any recruitment services. Moreover, we will never ask you for money in exchange for employment opportunities or other similar services. Any such offer of employment or any other service in exchange for fees that claims to be from us is deceitful and part of a fraud.

Criminal and/or civil liabilities may arise from such actions and we intend to cooperate with competent law enforcement agencies. Accordingly, we would ask you to immediately get in touch with us upon receiving a suspicious offer or claim and additionally notify the police or other competent authority.

In any case, please disregard any written or oral request related to a job offer or an interview that you believe is or might be fraudulent or suspicious.

Please note that under no circumstances shall Menarini Group be held liable or responsible for any claims, losses, damages, expenses or other inconvenience resulting from or in any way connected to the actions of these imposters.